שווי הפעילות העסקית: Actinium Pharmaceuticals (ATNM)

This daily price chart for Actinium Pharmaceuticals (ATNM) demonstrates an enterprise value of 12.98. Actinium Pharmaceuticals (ATNM) minimizes isotope shortage risks through strategic partnerships with external production sites. The business targets oncology centers, offering targeted irradiation to improve bone marrow transplant efficacy for leukemia. Capitalization growth is expected driven by FDA approval of Iomab-B and new clinical results.

Enterprise Value (EV) represents the total buyout price of a business, combining market capitalization and net debt. This metric allows an investor to assess the actual cost of acquiring assets by eliminating distortions caused by cash holdings. The trend in the company's total capital valuation reflects the real-time assessment of the business. For Actinium Pharmaceuticals (ATNM), this figure is based exclusively on expectations of regulatory drug approval. The absence of current revenue makes EV an indicator of the speculative value of future biotechnological developments.